Biosimilars are drugs whose effects are similar to those of biopharmaceuticals and are sold by a different manufacturer once the original drugs’ patent expires, pharmalive.com reported.
The joint venture will take advantage of Fujifilm’s production technology, quality control technology and Kyowa Hakko Kirin’s technologies in biopharmaceutical R&D and manufacturing.
The project intends to develop production processes and achieve cost reduction for biosimilars.
In addition, the venture hopes to commence the clinical trial for the first drug candidate by 2013.